Advances in Bone‐targeted Drug Delivery Systems for Neoadjuvant Chemotherapy for Osteosarcoma |
| |
| Authors: | Cheng‐jun Li MD Xiao‐zhou Liu MD Lei Zhang MD Long‐bang Chen MD Xin Shi MD Su‐jia Wu MD Jian‐ning Zhao MD |
| |
| Affiliation: | Department of Orthopaedics, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China |
| |
| Abstract: | Targeted therapy for osteosarcoma includes organ, cell and molecular biological targeting; of these, organ targeting is the most mature. Bone‐targeted drug delivery systems are used to concentrate chemotherapeutic drugs in bone tissues, thus potentially resolving the problem of reaching the desired foci and minimizing the toxicity and adverse effects of neoadjuvant chemotherapy. Some progress has been made in bone‐targeted drug delivery systems for treatment of osteosarcoma; however, most are still at an experimental stage and there is a long transitional period to clinical application. Therefore, determining how to combine new, polymolecular and multi‐pathway targets is an important research aspect of designing new bone‐targeted drug delivery systems in future studies. The purpose of this article was to review the status of research on targeted therapy for osteosarcoma and to summarize the progress made thus far in developing bone‐targeted drug delivery systems for neoadjuvant chemotherapy for osteosarcoma with the aim of providing new ideas for highly effective therapeutic protocols with low toxicity for patients with osteosarcoma. |
| |
| Keywords: | Cell‐targeted therapy Drug delivery system Molecular biological targets Organ‐targeted therapy Osteosarcoma |
|
|
